MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

extranodal NK/T-cell lymphoma

  • Home
  • extranodal NK/T-cell lymphoma
Distinct Myeloid Landscapes Define Prognostic Niches in Extranodal NK/T-Cell Lymphoma
Posted inHematology-Oncology news Pathology & Lab Medicine/Bệnh học

Distinct Myeloid Landscapes Define Prognostic Niches in Extranodal NK/T-Cell Lymphoma

Posted by By MedXY 08/28/2026
Spatial multimodal profiling reveals two macrophage-defined ENKTL subgroups with distinct tumor-myeloid interactions influencing prognosis and potential immunotherapy targets.
Read More
Navigating Dual Resistance in Extranodal NK/T-Cell Lymphoma: Challenges and Emerging Insights
Posted inHematology-Oncology news Oncology

Navigating Dual Resistance in Extranodal NK/T-Cell Lymphoma: Challenges and Emerging Insights

Posted by By MedXY 07/15/2026
Dual resistance to asparaginase and PD-1 inhibitors in extranodal NK/T-cell lymphoma leads to poor prognosis; chidamide-containing regimens show promising survival benefits in this difficult-to-treat population.
Read More
  • Evaluating Beta Cell Function in Preclinical Type 1 Diabetes Using CGM-Derived Disposition Index
  • Menstrual Cycle Influence on Exercise Performance: The Role of Cramp Severity and Psychological Factors in Active Women
  • Innovative Optical Tracking Enhances Upper Extremity Joint Assessment in Burn Patients
  • Comparative 1-Year Evaluation of 3D-Printed Resin Crowns Versus Monolithic Zirconia Crowns for Posterior Prostheses
  • Facilitated vs Self-Guided Advance Care Planning in Black and White Older Adults: Insights from the EQUAL ACP Randomized Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top